Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...

A yearslong partner of neuroscience player Sage, Biogen already owns 10.2% of the Cambridge, Massachusetts-based biotech, ...

Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...

Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...

The proposed deal comes soon after Sage implemented a restructuring plan to focus on Zurzuvae’s launch in postpartum ...

The $7.22-per-share deal for 89.8% of Sage is a 30% premium on the company's share price on Friday and is estimated by ...

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

Sage Therapeutics’ shares jumped over 45% to $8.09 in after-hours on Friday, after the company confirmed that biotech major ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...

Sage Therapeutics, Inc. (Nasdaq: SAGE) (“The Company”), today confirmed that Biogen Inc. (Nasdaq: BIIB) (“Biogen”) has ...

As I ran from interview to interview across San Francisco, I was consistently warmed by the stories I was told by biotech and ...

Sage Therapeutics (SAGE) stock jumped on Friday as Biogen (BIIB) made a bid to acquire the stake it currently doesn't own for ...